Intervention with methotrexate in patients with arthralgia at risk of rheumatoid arthritis to reduce the development of persistent arthritis and its disease burden (TREAT EARLIER): a randomised, double-blind, placebo-controlled, proof-of-concept trial

医学 类风湿性关节炎 安慰剂 关节炎 内科学 临床终点 痹症科 物理疗法 甲氨蝶呤 临床试验 随机对照试验 亚临床感染 外科 替代医学 病理
作者
Doortje I Krijbolder,M. Verstappen,Bastiaan T van Dijk,Yousra J. Dakkak,L.E. Burgers,Aleid C. Boer,Yune Jung Park,Marianne E de Witt-Luth,Karen Visser,Marc R. Kok,Esmeralda T. H. Molenaar,Pascal H P de Jong,Stefan Böhringer,T. Huizinga,Cornelia F Allaart,Ellis Niemantsverdriet,Annette H M van der Helm–van Mil
出处
期刊:The Lancet [Elsevier BV]
卷期号:400 (10348): 283-294 被引量:97
标识
DOI:10.1016/s0140-6736(22)01193-x
摘要

Rheumatoid arthritis is the most common autoimmune disease worldwide and requires long-term treatment to suppress inflammation. Currently, treatment is started when arthritis is clinically apparent. We aimed to evaluate whether earlier intervention, in the preceding phase of arthralgia and subclinical joint inflammation, could prevent the development of clinical arthritis or reduce the disease burden.We conducted a randomised, double-blind, placebo-controlled, proof-of-concept-trial at the Leiden University Medical Centre, Leiden, Netherlands. Adults aged 18 years or older with arthralgia clinically suspected of progressing to rheumatoid arthritis and MRI-detected subclinical joint inflammation were eligible for enrolment across 13 rheumatology outpatient clinics in the southwest region of the Netherlands and randomly assigned (1:1) to a single intramuscular glucocorticoid injection (120 mg) and a 1-year course of oral methotrexate (up to 25 mg/week), or placebo (single injection and tablets for 1 year). Participants and investigators were masked to group assignment. Follow-up continued for 1 year after the end of the 1-year treatment period. The primary endpoint was development of clinical arthritis (fulfilling the 2010 rheumatoid arthritis classification criteria or involving two or more joints) that persisted for at least 2 weeks. Patient-reported physical functioning, symptoms, and work productivity were secondary endpoints, which were measured every 4 months. Additionally, the course of MRI-detected inflammation was studied. All participants entered the intention-to-treat analysis. This trial is registered with EudraCT, 2014-004472-35, and the Netherlands Trial Register, NTR4853-trial-NL4599.Between April 16, 2015, and Sept 11, 2019, 901 patients were assessed for eligibility and 236 were enrolled and randomly assigned to active treatment (n=119) or placebo (n=117). At 2 years, the frequency of the primary endpoint was similar between the groups (23 [19%] of 119 participants in the treatment group vs 21 [18%] of 117 in the placebo group; hazard ratio 0·81, 95% CI 0·45 to 1·48). Physical functioning improved more in the treatment group during the first 4 months and remained better than in the placebo group (mean between-group difference in Health Assessment Questionnaire disability index over 2 years: -0·09, 95% CI -0·16 to -0·03; p=0·0042). Similarly, pain (on scale 0-100, mean between-group difference: -8, 95% CI -12 to -4; p<0·0001), morning stiffness of joints (-12, -16 to -8; p<0·0001), presenteeism (-8%, -13 to -3; p=0·0007), and MRI-detected joint inflammation (-1·4 points, -2·0 to -0·9; p<0·0001) showed sustained improvement in the treatment group compared with the placebo group. The number of serious adverse events was equal in both groups; adverse events were consistent with the known safety profile for methotrexate.Methotrexate, the cornerstone treatment of rheumatoid arthritis, initiated at the pre-arthritis stage of symptoms and subclinical inflammation, did not prevent the development of clinical arthritis, but modified the disease course as shown by sustained improvement in MRI-detected inflammation, related symptoms, and impairments compared with placebo.Dutch Research Council (NWO; Dutch Arthritis Society).
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
fxy完成签到 ,获得积分10
1秒前
合适的幻然完成签到,获得积分10
1秒前
沐雨汐完成签到,获得积分10
3秒前
5秒前
6秒前
jiayoujijin完成签到 ,获得积分10
6秒前
淡然思卉完成签到,获得积分10
7秒前
争当科研巨匠完成签到,获得积分10
7秒前
英姑应助认真的刺猬采纳,获得10
14秒前
好大一只小坏蛋完成签到,获得积分20
14秒前
站走跑完成签到 ,获得积分10
17秒前
步步高完成签到,获得积分10
19秒前
无私的雪瑶完成签到 ,获得积分10
19秒前
小杨完成签到,获得积分20
20秒前
小花完成签到 ,获得积分10
25秒前
宁夕完成签到 ,获得积分10
29秒前
西宁完成签到,获得积分10
29秒前
拼搏的羊青完成签到 ,获得积分10
30秒前
科目三应助asd113采纳,获得10
30秒前
deng203完成签到 ,获得积分20
32秒前
33秒前
时米米米完成签到,获得积分10
33秒前
浅浅完成签到,获得积分10
37秒前
量子星尘发布了新的文献求助10
42秒前
帅气的藏鸟完成签到,获得积分10
46秒前
加油完成签到 ,获得积分10
47秒前
健康的宛菡完成签到 ,获得积分10
48秒前
橙果果发布了新的文献求助20
48秒前
晚晚完成签到,获得积分10
49秒前
49秒前
听闻韬声依旧完成签到 ,获得积分10
49秒前
ZHZ完成签到,获得积分10
50秒前
啊哈啊哈额完成签到,获得积分10
50秒前
yyy完成签到,获得积分10
51秒前
51秒前
xiaoputaor完成签到 ,获得积分10
52秒前
Camus发布了新的文献求助10
52秒前
paper reader完成签到,获得积分10
52秒前
53秒前
八八九九九1完成签到,获得积分10
54秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Handbook of Industrial Diamonds.Vol2 1100
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038066
求助须知:如何正确求助?哪些是违规求助? 3575779
关于积分的说明 11373801
捐赠科研通 3305584
什么是DOI,文献DOI怎么找? 1819239
邀请新用户注册赠送积分活动 892655
科研通“疑难数据库(出版商)”最低求助积分说明 815022